HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

MHRA

Regulatory intelligence
MHRAapproval72% confidence

Clinical trials for medicines: modifying a clinical trial approval

Source: MHRA

Why This Matters

Why this matters: illustrates how regulators handled a comparable approval decision relevant to Roche.

Regulatory Analysis

Guidance on the various types of modifications that can be made to a clinical trial approval.

Supporting Context

Therapeutic area
Neurology · Spinal Muscular Atrophy
Sub-indication
General

Related signal: Risdiplam Study to Assess Real-World Outcomes in Type I and II SMA

Source

View source document

Related Signal

Open signal — Risdiplam Study to Assess Real-World Outcomes in Type I and II SMA
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.